Resistoflavine, cytotoxic compound from a marine actinomycete, Streptomyces chibaensis AUBN1/7

School of Pharmacy, International Medical University, Sesama Center, Plaza, Komanwel, Bukit jalil, 57000 Kuala Lumpur, Malaysia.
Microbiological Research (Impact Factor: 1.94). 02/2007; 162(4):322-7. DOI: 10.1016/j.micres.2006.01.012
Source: PubMed

ABSTRACT In our systematic screening programme for marine actinomycetes, a bioactive Streptomycete was isolated from marine sediment samples of Bay of Bengal, India. The taxonomic studies indicated that the isolate belongs to Streptomyces chibaensis and it was designated as S. chibaensis AUBN1/7. The isolate yielded a cytotoxic compound. It was obtained by solvent extraction followed by the chromatographic purification. Based on the spectral data of the pure compound, it was identified as quinone-related antibiotic, resistoflavine (1). It showed a potent cytotoxic activity against cell lines viz. HMO2 (Gastric adenocarcinoma) and HePG2 (Hepatic carcinoma) in vitro and also exhibited weak antibacterial activities against Gram-positive and Gram-negative bacteria.

Download full-text


Available from: Saisha Vinjamuri, Mar 06, 2014
  • [Show abstract] [Hide abstract]
    ABSTRACT: Secondary metabolites obtained from Actinomycetales provide a potential source of many novel compounds with antibacterial, antitumour, antifungal, antiviral, antiparasitic and other properties. The majority of these compounds are widely used as medicines for combating multidrug-resistant Gram-positive and Gram-negative bacterial strains. Members of the genus Streptomyces are profile producers of previously-known secondary metabolites. Actinomycetes have been isolated from terrestrial soils, from the rhizospheres of plant roots, and recently from marine sediments. This review demonstrates the diversity of secondary metabolites produced by actinomycete strains with respect to their chemical structure, biological activity and origin. On the basis of this diversity, this review concludes that the discovery of new bioactive compounds will continue to pose a great challenge for scientists.
    Central European Journal of Biology 06/2012; 7(3). DOI:10.2478/s11535-012-0036-1 · 0.63 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Studies of the origin of bioactive metabolites of marine actinomycetes are reviewed. Structures and properties of new metabolites from indigenous marine bacteria from Actinomycetales order, such as a benzanthraquinone antibiotic from a strain of the Chainia purpurogena, istamycins, aplasmomycins, altemicidin, new phenazine esters. C13-butanolide, marinone and debromomarinone, palmyromycin, urauchimicins and some others compounds are presented. Prospects of marine biotechnology and microbiology (with considerable emphasis on the development of the basis biology of marine microorganisms in cultures collection) are discussed.
    Bioorganicheskaia khimiia 02/1995; 21(1):3-8.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Actinomycetes are one of the most efficient groups of secondary metabolite producers and are very important from an industrial point of view. Among its various genera, Streptomyces, Saccharopolyspora, Amycolatopsis, Micromonospora and Actinoplanes are the major producers of commercially important biomolecules. Several species have been isolated and screened from the soil in the past decades. Consequently the chance of isolating a novel actinomycete strain from a terrestrial habitat, which would produce new biologically active metabolites, has reduced. The most relevant reason for discovering novel secondary metabolites is to circumvent the problem of resistant pathogens, which are no longer susceptible to the currently used drugs. Existence of actinomycetes has been reported in the hitherto untapped marine ecosystem. Marine actinomycetes are efficient producers of new secondary metabolites that show a range of biological activities including antibacterial, antifungal, anticancer, insecticidal and enzyme inhibition. Bioactive compounds from marine actinomycetes possess distinct chemical structures that may form the basis for synthesis of new drugs that could be used to combat resistant pathogens.
    Indian Journal of Microbiology 12/2008; 48(4):410-31. DOI:10.1007/s12088-008-0052-z · 0.83 Impact Factor